Bromfenac versus betamethasone in diabetic macular oedema
31 October 2023
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
|
Diabetic macular edema, betamethasone, bromfenac, central subfield thickness, intraocular pressure
This is a randomised, prospective, single-centre trial in patients diagnosed with diabetic macular oedema (DMO) with central subfield thickness (CST) of 250-500µm, who refused anti-VEGF treatment. Nineteen eyes of 19 patients were randomised to bromfenac (BF) or betamethasone (BM) drops,...
